MALAT1 and breast cancer: Despite these limitations, the present study still demonstrated that MALAT1 signature was associated with patient survival, and might potentially be used as a new independent prognostic marker to predict the OS of breast cancer patients for diagnosis age below 60 or infiltrating ductal carcinoma.